DaVita Inc. $DVA Shares Sold by Aberdeen Group plc

Key Points

• Aberdeen Group plc significantly reduced its stake in DaVita Inc. by 76.9%, selling 140,420 shares and retaining only 42,253 shares valued at approximately $6.4 million.
• Recent analyst evaluations have seen DaVita's stock rating upgraded to "buy" by Wall Street Zen, while Barclays lowered its price target from $169.00 to $160.00.
• DaVita reported solid performance in its latest earnings, exceeding estimates with $2.95 earnings per share and revenue of $3.38 billion, marking a 6.1% year-over-year increase.

Aberdeen Group plc decreased its position in DaVita Inc. (NYSE:DVA - Free Report) by 76.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,253 shares of the company's stock after selling 140,420 shares during the quarter. Aberdeen Group plc owned 0.05% of DaVita worth $6,408,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Iron Triangle Partners LP purchased a new stake in shares of DaVita during the fourth quarter worth $38,946,000. GAMMA Investing LLC increased its position in shares of DaVita by 14,695.8% during the first quarter. GAMMA Investing LLC now owns 234,809 shares of the company's stock worth $35,919,000 after acquiring an additional 233,222 shares during the period. Nuveen LLC purchased a new stake in shares of DaVita during the first quarter worth $20,218,000. Rovin Capital UT ADV purchased a new stake in shares of DaVita during the first quarter worth $18,442,000. Finally, Deutsche Bank AG increased its position in shares of DaVita by 35.2% during the fourth quarter. Deutsche Bank AG now owns 392,422 shares of the company's stock worth $58,687,000 after acquiring an additional 102,230 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

Insider Transactions at DaVita

In other DaVita news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the transaction, the insider owned 26,038 shares in the company, valued at $3,905,700. This represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on DVA shares. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research report on Friday. Truist Financial set a $148.00 price objective on DaVita in a research report on Friday, August 8th. Finally, Barclays cut their price objective on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 7th. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $164.00.

DaVita Stock Performance

NYSE DVA traded up $1.29 during trading hours on Tuesday, hitting $138.62. The company had a trading volume of 951,923 shares, compared to its average volume of 870,523. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. DaVita Inc. has a 1-year low of $126.07 and a 1-year high of $179.60. The company has a market cap of $9.91 billion, a PE ratio of 13.63, a price-to-earnings-growth ratio of 0.98 and a beta of 1.09. The business has a 50 day moving average of $139.66 and a 200-day moving average of $143.41.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The company had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter in the prior year, the firm posted $2.00 earnings per share. DaVita's revenue for the quarter was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, equities research analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.